No Data
JUNSHI BIO (01877) has signed a distribution and commercialization agreement for Trelagliptin with LEO Pharma.
JUNSHI BIO (01877) announced that recently, its wholly-owned subsidiary TopAlliance Bio...
Express News | Shanghai Junshi Biosciences - Entering Into Distribution and Marketing Agreement With Leo Pharma
Express News | Junshi Biosciences Announces Commercialization Partnership With Leo Pharma for Toripalimab in Europe
Express News | Shanghai Junshi Biosciences Says Unit Signs Distribution and Commercialization Agreements With Leo Pharma A/S
JUNSHI BIO (688180.SH): signed a distribution and commercialization agreement with LEO Pharma.
Gelonghui, January 20th丨JUNSHI BIO (688180.SH) announced that its wholly-owned subsidiary TopAlliance Biosciences Inc. (referred to as "TopAlliance") has signed a "Distribution and Commercialization Agreement" (referred to as "this agreement") with LEO Pharma A/S (referred to as "LEO Pharma"). According to this agreement, TopAlliance will grant LEO Pharma the right to store, distribute, promote, and market in all existing member states of the European Union (EU) and the European Economic Area (EEA), any future member states, as well as in Switzerland and the United Kingdom (referred to as "cooperation area").
Research Reports Digging for Opportunities | Founder Securities: JUNSHI BIO's revenue in 2024 exceeds expectations, with significantly reduced losses, maintaining a "strong buy" rating.
According to a Research Report from Founder Securities, Shanghai Junshi Biosciences Co., Ltd. (688180.SH) is expected to have a revenue of 1.949 billion yuan in 2024, representing a year-on-year increase of 29.71%, with a net income of -1.292 billion yuan, a year-on-year loss reduction of 43.42%. The company exceeded revenue expectations, and losses significantly narrowed. The increase in revenue is attributed to the improved sales efficiency of the commercialization team, and it is anticipated that domestic sales of the core product Toripalimab will increase significantly; it has currently received approval for ten indications, all of which are included in the health insurance coverage. Toripalimab is expected to ramp up sales globally in 2025-2026. In addition, the company has three other commercialized products.
Further Weakness as Shanghai Junshi Biosciences (HKG:1877) Drops 3.2% This Week, Taking Three-year Losses to 83%
